Atopic Dermatitis Clinical Trial
— NiPPeR ChildOfficial title:
Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health - Child Health and Well-being Follow Up Study
Verified date | June 2023 |
Source | University of Southampton |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is an increasing focus on the need to optimise nutrition, lifestyle and metabolism of parents before and during pregnancy and of the infant after birth, but as yet there is limited understanding of the specific influences and of the underlying mechanisms. This study is a follow up of children from the NiPPeR trial of a nutritional drink enriched with micronutrients, myo-inositol and probiotics taken preconception and during pregnancy. In this setting we will examine the influence of parental nutrition, lifestyle and metabolism before and during pregnancy on child growth, development and well-being; ascertaining growth, adiposity, metabolism, neurobehavioural and health outcomes in the children, and characterising the underlying mechanisms. The data collected will allow identification of the contributions of parental and offspring characteristics, nutritional, lifestyle and medical factors, social and economic status, ethnicity, genetics, metabolism and microbes to promoting healthy growth, body composition and wellbeing in the children.
Status | Enrolling by invitation |
Enrollment | 510 |
Est. completion date | August 30, 2026 |
Est. primary completion date | August 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 8 Years |
Eligibility | Inclusion Criteria: All children still participating in the NiPPeR study at 6-8 years. Exclusion Criteria: Known significant congenital anomaly or genetic condition that influences child growth or neurodevelopment. |
Country | Name | City | State |
---|---|---|---|
New Zealand | The University of Auckland | Auckland | |
Singapore | National University Hospital | Singapore | |
United Kingdom | University Hospital Southampton | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Southampton | Auckland UniServices Ltd., National University Health System, Singapore, National University Hospital, Singapore, National University of Singapore, Singapore Institute for Clinical Sciences, University of Auckland, New Zealand |
New Zealand, Singapore, United Kingdom,
Godfrey KM, Barton SJ, El-Heis S, Kenealy T, Nield H, Baker PN, Chong YS, Cutfield W, Chan SY; NiPPeR Study Group. Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. Diabetes Care. 2021 May;44(5):1091-1099. doi: 10.2337/dc20-2515. Epub 2021 Mar 29. — View Citation
Godfrey KM, Cutfield W, Chan SY, Baker PN, Chong YS; NiPPeR Study Group. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials. 2017 Mar 20;18(1):131. doi: 10.1186/s13063-017-1875-x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Healthcare utilisation (US$) | Health economics analysis of child outcomes | Up to age 8 years, from periconception to age 8 years | |
Primary | Child Body Mass Index (kg/m2), derived from weight and height | Child size and body composition | Up to age 8 years, from periconception to age 8 years | |
Primary | Intellectual function (WASI-II IQ [4 sub-test scores], higher score is a higher IQ) | Child cognition | Up to age 8 years, from periconception to age 8 years | |
Primary | Child insulin resistance (HOMA2-IR [no units], higher value is greater insulin resistance) | Child insulin resistance | Up to age 8 years, from periconception to age 8 years | |
Primary | Dimensional Change Card Sort Test (raw & T-scores) | Child executive functioning - NIH Toolbox Cognition Battery component | Up to age 8 years, from periconception to age 8 years | |
Primary | Flanker Inhibitory Control & Attention Test (raw & T-scores) | Child executive functioning - NIH Toolbox Cognition Battery Component | Up to age 8 years, from periconception to age 8 years | |
Primary | Strengths & Difficulties Questionnaire score (no units) | Child neurobehavioural functioning | Up to age 8 years, from periconception to age 8 years | |
Primary | Child Behaviour Check List score (no units) | Child neurobehavioural functioning | Up to age 8 years, from periconception to age 8 years | |
Secondary | Body fat mass (kg, % and indices) | Obesity and body composition | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in body fat mass (kg) | Adiposity gain | Up to age 8 years, from periconception to age 8 years | |
Secondary | Body lean mass (kg, % and indices) | Child body composition - lean mass | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in lean mass (kg) | Lean mass gain | Up to age 8 years, from periconception to age 8 years | |
Secondary | Body bone mass (kg, % and indices) | Child body composition - bone mass | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in bone mass (kg) | Bone mass gain | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child height (cm) | Child height | Up to age 8 years, from periconception to age 8 years | |
Secondary | Height growth (cm) | Linear growth | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in body mass index (z-score & percentile) | Change in BMI | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in weight (kg) | Weight gain | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child mid-upper arm circumference (cm) | Child arm circumference | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in mid-upper circumference (z-score) | Change in soft tissue mass | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child waist circumference (cm) | Child waist circumference | Up to age 8 years, from periconception to age 8 years | |
Secondary | Change in waist circumference (z-score) | Adiposity gain | Up to age 8 years, from periconception to age 8 years | |
Secondary | Heart rate response to step test (beats per minute) | Cardiovascular fitness and function | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child blood pressure (mm Hg) | Cardiovascular fitness and function | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child resting heart rate (beats per minute) | Cardiovascular fitness and function | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child minutes to return to resting heart rate (minutes) | Cardiovascular fitness and function | Up to age 8 years, from periconception to age 8 years | |
Secondary | Diagnosed medical conditions or disorders ascertained by questionnaire, including child medical conditions, infections, gastrointestinal, cardiovascular, respiratory, dermatological, neuropsychological, mental and musculoskeletal health and wellbeing | Child health and wellbeing | Up to age 8 years, from periconception to age 8 years | |
Secondary | Dietary patterns ascertained by frequency questionnaires | Child diet | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child Eating Behaviour Questionnaire | Child eating behaviours | Up to age 8 years, from periconception to age 8 years | |
Secondary | Parental Feeding Practices Questionnaire | Parental feeding practices | Up to age 8 years, from periconception to age 8 years | |
Secondary | Children's Sleep Habits Questionnaire | Child sleep patterns | Up to age 8 years, from periconception to age 8 years | |
Secondary | Children's actigraphy measurements of activity behaviours [minutes/day] | Child physical activity, sleep and sedentary behaviours | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child Movement Behaviour Questionnaire | Child activity behaviours | Up to age 8 years, from periconception to age 8 years | |
Secondary | Skin pricks test results to allergens [mm] | Child atopic sensitisation | Up to age 8 years, from periconception to age 8 years | |
Secondary | Child asthma, wheezing illnesses, eczema, rhinitis and food allergy by clinical examination & questionnaires | Child atopic and allergic wellbeing and disorders | Up to age 8 years, from periconception to age 8 years | |
Secondary | Hair metabolome panel concentrations (pmol/L) | Biomarkers of health and wellbeing measured in hair samples | Up to age 8 years, from periconception to age 8 years | |
Secondary | Urine micronutrient concentrations (nmol/L) | Child micronutrient status | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood micronutrient concentrations (nmol/L) | Child circulating micronutrient profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood trace element concentrations (pmol/L) | Child circulating trace element profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Urine trace element concentrations (pmol/L) | Child trace element status | Up to age 8 years, from periconception to age 8 years | |
Secondary | Stool metagenomic profile (abundance) | Child gut microbiota composition | Up to age 8 years, from periconception to age 8 years | |
Secondary | Skin metagenomic profile (abundance) | Child skin microbiota composition | Up to age 8 years, from periconception to age 8 years | |
Secondary | Stool metatranscriptomic profile (relative activity) | Child gut microbiota activity profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Skin metatranscriptomic profile (relative activity) | Child skin microbiota activity profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Stool metabolomic profile (pmol/L) | Child gut microbiota metabolite profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Skin metabolomic profile (pmol/L) | Child skin microbiota metabolite profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood molecular profile (% methylation) | Child blood epigenetic profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Buccal molecular profile (% methylation) | Child buccal cell epigenetic profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood transcriptomic profile (relative expression) | Child blood transcriptomic profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Buccal transcriptomic profile (relative expression) | Child buccal cell transcriptomic profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Genetic variation (DNA sequence analysis) | Genetic variant analysis | Up to age 8 years, from periconception to age 8 years | |
Secondary | Circulating chemocytokine measurements (nmol/L) | Child chemocytokine profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Circulating adipokine measurements (nmol/L) | Child adipokine profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Circulating inflammatory marker measurement (nmol/L) | Child inflammatory factor profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Plasma glucose concentration (mmol/L) | Child's plasma glycemia | Up to age 8 years, from periconception to age 8 years | |
Secondary | Plasma lipid concentrations (mmol/L) | Child's metabolic profile - lipid concentrations | Up to age 8 years, from periconception to age 8 years | |
Secondary | Plasma high-sensitivity C-reactive protein concentrations (mmol/L) | Child's inflammatory marker status | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood metabolome panel concentrations (pmol/L) | Child's blood metabolomic status | Up to age 8 years, from periconception to age 8 years | |
Secondary | Urine metabolome panel concentrations (pmol/L) | Child's urine metabolomic status | Up to age 8 years, from periconception to age 8 years | |
Secondary | Urine measurement of environmental pollutant exposure (pmol/L) | Urine exposome pollutant profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Blood measurement of environmental pollutant exposure (ng/gm lipid) | Blood exposome pollutant profile | Up to age 8 years, from periconception to age 8 years | |
Secondary | Hair measurement of environmental pollutant exposure (pmol/L) | Hair exposome pollutant profile | Up to age 8 years, from periconception to age 8 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |